Melanoma: BRAFi Rechallenge

Melanoma: BRAFi Rechallenge

Melanoma is the most aggressive type of skin cancer. Half of melanoma cases are characterized by the mutation BRAF V600. The case presented concerns a 41-year-old patient with locally advanced melanoma, being positive in mutation BRAF V600. The patient underwent surgery and received additional targe...

Full description

Bibliographic Details
Main Authors:	Christoforos S. Kosmidis, Konstantina Papadopoulou, Chrysi Maria Mystakidou, Evanthia Papadopoulou, Stylianos Mantalovas, Nikolaos Varsamis, Charilaos Koulouris, Vasiliki Theodorou, Konstantinos Papadopoulos, Christina Sevva, Petrina Miltiadous, Savvas Petanidis, Eleni Georgakoudi, Eleni Papadopoulou, Sofia Baka
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	Medicina
Subjects:	targeted therapy BRAFi rechallenge metastatic melanoma BRAF V600 mutation BRAF inhibitor
Online Access:	https://www.mdpi.com/1648-9144/59/5/975

Similar Items

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
by: Blessie Elizabeth Nelson, et al.
Published: (2024-03-01)

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
by: Anaïs Paris, et al.
Published: (2022-10-01)

Phytobezoar-Induced Mechanical Ileus and Incipient Intussusception: A Case Report
by: Christoforos S. Kosmidis, et al.
Published: (2023-06-01)

Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
by: Christoforos S. Kosmidis, et al.
Published: (2022-09-01)

Extramammary Paget’s Disease of the Vulva: Report of Two Cases
by: Christoforos S. Kosmidis, et al.
Published: (2021-09-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
by: O. I. Kit, et al.
Published: (2016-06-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib
by: Hiroshi Kato, et al.
Published: (2023-09-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
by: Dugan MM, et al.
Published: (2024-07-01)

Clinical associations and genetic interactions of oncogenic BRAF alleles
by: Sebastian A. Wagner
Published: (2022-10-01)

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review
by: Nina Yu, et al.
Published: (2024-12-01)

PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01)

The Prognostic Significance of BRAF Gene Analysis in Children and Adolescents with Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis
by: Eleni P Kotanidou, et al.
Published: (2023-03-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
by: Ernesto Rossi, et al.
Published: (2023-01-01)

Successful rechallenge with clozapine after discontinuation due to drug‐induced pneumonia: A case report
by: Yuki Kikuchi, et al.
Published: (2022-09-01)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
by: Sofia España Fernandez, et al.
Published: (2023-03-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
by: Manrose Singh, et al.
Published: (2024-08-01)

Hyperplastic Polyposis Syndrome Identified with a BRAF Mutation
Published: (2012-04-01)

Anal Canal Melanoma: Challenging the Odds
by: Sara Magno, et al.
Published: (2024-02-01)

Intrathymic Localization of Melanoma: A Brief Report of Two Cases and a Review of the Literature
by: Giorgio Cannone, et al.
Published: (2023-06-01)

Beneficial effects of vemurafenib on craniopharyngioma carrying BRAF-V600E mutation
by: WANG Xi, YE Ting, NIE Min, WU Xueyan, MAO Jiangfeng
Published: (2024-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
by: Matthew R. Kroll, et al.
Published: (2024-07-01)

Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study
by: Shweta Shah, et al.
Published: (2019-12-01)

RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy
by: Ahlem Jebali, et al.
Published: (2021-10-01)

Eruptive nevi in the setting of encorafenib: A case report and literature review
by: Marisa Lenga, BS, et al.
Published: (2025-02-01)

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
by: Hana Garaj, et al.
Published: (2024-01-01)

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
by: Michael P Smith, et al.
Published: (2017-06-01)

Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors
by: Damien M Rasmussen, et al.
Published: (2024-05-01)

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient
by: Sandro Anchisi, et al.
Published: (2023-12-01)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
by: Aleksandra Bożyk, et al.
Published: (2021-03-01)

Systemic and Craniospinal Rosai Dorfman Disease with Intraparenchymal, Intramedullary and Leptomeningeal Disease
by: Yi Li, et al.
Published: (2021-10-01)

Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons
by: Hui-Ai Zeng, et al.
Published: (2025-02-01)

Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance
by: Takehiro Nakao, et al.
Published: (2024-10-01)

Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies
by: L. Weiss, et al.
Published: (2025-03-01)

Molecular Susceptibility and Treatment Challenges in Melanoma
by: Kiran Kumar Kolathur, et al.
Published: (2024-08-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
by: Lovisa Falkman, et al.
Published: (2024-04-01)

Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo
by: Heike Niessner, et al.
Published: (2022-04-01)

Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis
by: Jiahui Cao, et al.
Published: (2024-12-01)

Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study
by: Mengya Guo, et al.
Published: (2024-12-01)